DHG is a depolymerized glycosaminoglycan extracted from the sea cucumber, Stichopus japonicus Selenka. We have demonstrated that DHG has antithrombotic and anticoagu lant activities distinct from those of heparin (1, 2) . In one of these studies (2), we showed that DHG had two different inhibitory activities in the blood coagulation cascade: HCII-dependent inhibition of thrombin; and ATIII and HCII-independent inhibition of factor X activation by factor IXa-factor VIIIa complex. The anticoagulant effect of DHG was very similar to that of PPS, which has been shown to inhibit thrombin HCII-dependently and to prolong APTT, ATIII and HCII-independently (3, 4) . Wagenvoord et al. (5) have reported that PPS inhibits both factor Villa formation (activation of factor VIII by thrombin) and the function of factor VIIIa, probably by the formation of a factor VIII(a)-PPS complex. Recently, heparin has been reported to inhibit the thrombin-catalyzed activation of factor VIII and also the activation of factor X by the intrinsic factor Xase in the absence of ATIII and HCII (6). Based on these published reports, we were prompted to further characterize the anticoagulant activity of DHG and to investigate the effect of DHG on the activation of factor VIII and factor V by thrombin in the absence of ATIII and HCII. In this study, we present evidence that DHG inhibits the activation of factor VIII by thrombin, making a binary complex with thrombin. The mechanism of the inhibition is discussed and compared with that of heparin. complex was kindly supplied by The Chemo-Sera-Thera peutic Foundation (Kumamoto). Fibrinogen in this prepa ration was removed by using a heparin cellulofine column (Chisso). APTT reagent (Actin ?? ) and PT reagent (activated thromboplastin) were purchased from American Dade (Aguada, Puerto Rico) and International Reagents (Kobe), respectively. Factor VIII-deficient plasma and factor V deficient plasma were purchased from George King Bio Medical (Overland Park, KS, USA). FITC was purchased from Wako Chemical Industries (Osaka). The molar con centrations of human factors VIII and V and thrombin were calculated from concentration units, using their specific activities and molecular weights (8) (9) (10) 
MATERIALS AND METHODS

RESULTS
Effect of DHG on the Activation of Factor VIII and Factor V by Thrombin- Figure  1 shows the time course of the activation of recombinant factor VIII (A), plasma derived factor VIII (B), and factor V (C) by thrombin in the absence or presence of various amounts of DHG. In these experiments, a mixture containing DHG and factor VIII or factor V was diluted 1:1,100 to eliminate the effect of DHG on the assay of factor VIII or factor V. DHG retarded the activation of recombinant factor VIII by thrombin at concentrations exceeding 80 nM. At concentrations of 0.8 to 8 uM, DHG retarded both the initial rate of factor VIII activation and the rate of the inactivation of factor VIII (Fig. 1A) . The inhibition of factor VIII activation by DHG was also observed when the plasma-derived factor VIII, or factor VIII-vWF complex, was used instead of the recom binant factor VIII (Fig. 1B) . This effect of DHG on factor VIII was very similar to that of heparin (6, 17) . On the other hand, the effect of DHG in inhibiting the activation of factor V by thrombin was negligible at concentrations of up to 8 uM (Fia. 1C). Effect of DHG on the Cleavage of Factor V by Throm bin-We examined the effect of DHG on the thrombin catalyzed cleavage of factor V by SDS-PAGE, followed by silver staining of the proteins, as described under "MATE RIALS AND METHODS" (Fig. 3) . It has been established that human thrombin cleaves human factor V (A1-A2-B-A3 -Cl-C2) at the carboxyl terminals of Arg709 Arg1018, and Arg1545 generating a heavy chain (A1-A2) and a light chain (A3-C1-C2) of factor Va (21) . As shown in Fig. 3 (lanes 2 and 10), human thrombin cleaved human factor V into three fragments (210, 110, and 73/76 kDa) after 30s of incubation and into two fragments (110 and 73/76 kDa) after 10 min of incubation. Factor V in lane 1 was faintly stained, whereas factor V fragments were strongly stained. These results indicate that the fragments of 110 and 73/76 kDa were the heavy chain and the light chain of factor Va, generated by the cleavage of Arg709 and Arg1545 respective ly. The result also indicates that a fragment with molecular mass of 210 kDa was generated by the cleavage of Arg1018, an d that this consisted of a part of the B domain and A3-C1-C2. With increases in the amount of DHG, genera tion of the light chain was inhibited, but generation of the 210-kDa fragment and the heavy chain was not significantly inhibited, as shown in Fig. 3 (lanes 3-9) . These results indicate that DHG did not inhibit the cleavage of Arg709 and Arg1018 but that it inhibited further cleavage of Arg1545 by the action of thrombin. As described in the previous section, DHG did not inhibit the activation of factor V in terms of the measurement of factor Va cofactor activity. Therefore, our results demonstrate that the generation of factor Va activity was not inhibited by DHG despite the inhibition of the generation of light chain. This result is consistent with the observation of Monkovic and Tracy (22) and with the recently published report of Keller et al. (23) that the cleavage at Arg1018 was sufficient for the expression of factor Va cofactor activity. Affinity of Factors VIII and V and Thrombin to DHG -Cellulofine-Recombinant factor VIII, factor V, and throm bin were applied, respectively, to a DHG-cellulofine column to examine the interaction with DHG (Fig. 4) . They did not bind to a control column (acetylated amino cellulofine) at a physiological salt concentration (0.15 M NaCl), as indicated by the open circles in Fig. 4 . Thrombin and factor V bound to DHG-cellulofine under the same conditions and were eluted at 0.37 and 0.55 M NaCl, respectively (Fig. 4, A and  C) . Recombinant factor VIII did not bind to DHG-cellulo fine, but it had slight affinity for DHG, as shown by the peak of the passed-through fraction being broader than that of the control column (Fig. 4B) . These results indicate that DHG has strong affinity for factor V and thrombin but slight affinity for recombinant factor VIII.
Interaction of DHG with Thrombin-DHG was labeled with FITC to monitor the interaction with thrombin, as described under "MATERIALS AND METHODS." To demon strate that the labeling procedure did not affect the binding activity of DHG, we measured the competitive binding of FITC-DHG with nonlabeled DHG to thrombin. As shown in Fig. 5 , the change in fluorescence was proportional to the percentage of FITC-DHG to total DHG, that is, 50% substitution of FITC-DHG with nonlabeled DHG caused a 50% change in fluorescence. This result indicates that the affinity of FITC-DHG for thrombin was the same as that of nonlabeled DHG. Moreover, APTT prolongation by FITC DHG was almost the same as that brought about by nonlabeled DHG (data not shown). These results suggest that the functional activity of DHG was not changed by the labeling procedure. Figure 6 shows the stoichiometry for the interaction of DHG and thrombin. The ratio of throm bin to DHG was calculated to be 2.1 to 1, indicating that 1 mol of DHG bound 2 mol of thrombin. The dissociation con it for the thrombin-DHG complex was determined 
DISCUSSION
The major effect of glycosaminoglycans such as heparin and dermatan sulfate as antithrombotic agents has been estab lished: namely, they accelerate the inactivation of throm bin by ATIII or HCII, forming a ternary complex through their specific interaction (24) . However, recent studies have demonstrated that heparin also has ATIII-indepen dent inhibitory activity toward the activation of factor X by the factor IXa-factor VIIIa complex (25) and toward the activation of factor VIII by thrombin (6, 17) . In our previous study, we demonstrated that a glycosaminoglycan from the sea cucumber, DHG, had inhibitory activity toward the activation of factor X by the factor IXa-factor Villa complex, in addition to showing HCII-dependent inhibition of thrombin (2) . The intrinsic factor Xase inhibi tion exerted by DHG was more potent than that of heparin an d dermatan sulfate (2, 25) . In the present study, we have presented evidence that DHG has inhibitory activity toward the activation of factor VIII by thrombin. The effect was confirmed by the measurement of factor VIIIa activity and by monitoring the limited cleavage of factor VIII on SDS-PAGE. The generation of factor Villa activity from factor VIII and the cleavage of factor VIII light chain by thrombin were inhibited with increasing amounts of DHG. Although the effect of DHG on the cleavage of factor VIII heavy chain was not examined, the results indicated that DHG had the inhibitory activity toward factor VIII activa tion. Therefore, together with the previous findings (2), the present paper indicates that DHG has the three different inhibitory activities toward blood coagulation cascade reactions: (a) inhibition of factor VIII activation by throm bin, (b) inhibition of factor X activation by factor IXa factor VIIIa complex, and (c) the HCII-dependent inhibi In contrast to its effect on the activation of factor VIII by thrombin, DHG did not inhibit the activation of factor V by thrombin. Nonetheless, factor V showed high affinity to DHG-cellulofine and DHG inhibited the cleavage of one of three arginyl peptide bonds of factor V (Arg1545) by throm bin. From these results, we speculate that a ternary complex of thrombin, DHG and factor V was formed, but that the active site of thrombin was accessible to two of three arginyl peptide bonds of factor V (Arg709 and Arg1018) leading to the generation of factor Va activity.
The findings of recent reports and of this study show that sulfated polysaccharides have multiple functions in the blood coagulation cascade: first, inhibition of the interac tion of the factor IXa-factor VIIIa complex with factor X; second, inhibition of the interaction of thrombin with factor VIII; and third, acceleration of complex formation of ATIII with thrombin, factor Xa, or factor IXa and of HCII with thrombin. Heparin, dermatan sulfate, DHG, and pentosan polysulfate (PPS) affect these three reactions to different degrees. Heparin strongly interacts with ATIII, in contrast to the other three sulfated polysaccharides (30) . The inhibitory effect of heparin on the thrombin-mediated feedback reaction has been demonstrated to be of crucial importance (31, 32) . DHG and PPS show characteristic features in their strong interaction with the factor IXa factor VIIIa complex and with thrombin in the absence of ATIII. On the other hand, the major effect of heparin is thought to be its acceleration of the inactivation of throm bin by ATIII, due to the strong affinity of heparin for ATIII, through a unique pentasaccharide sequence (33) , and due to the high concentration of ATIII in plasma. These multiple functions of sulfated polysaccharides are presumed to be caused by a binary or ternary complex formed through the specific binding sites of these proteins. It is clear that the different potency of these glycosaminoglycans is due to the different structures of the oligosaccharide unit. The potency of DHG, a sulfated fucose-branched chondroitin sulfate E, is clearly different from that of dermatan sulfate (chondroitin sulfate B) (2) and chondroitin sulfate E (34), whose major action is the inactivation of thrombin through HCII; these characteristics suggest the important role of the sulfated fucose residue of DHG. The degree of sulfation (mean number of sulfate groups per saccharide) of the polysaccharides is also important for their function. The degree of sulfation of DHG was 1.3, which is higher than those of dermatan sulfate and chondroitin sulfates (7) . Thus, it is likely that the charge density of the sulfated polysaccharides may be important for the binding of the factor IXa-factor VIIIa complex and thrombin, and for determining the capacity to inhibit intrinsic factor Xase complex and factor VIII activation by thrombin. Although the function of DHG is qualitatively the same as that of PPS in vitro, DHG has been shown to be a more promising antithrombotic drug, with minimized hemorrhagic side effects (Kitazato et al., manuscript submitted), than PPS an d other sulfated polysaccharides (35) (36) (37) . It remains to be elucidated why DHG, unlike PPS, exerts an antithrom botic effect without producing any significant hemorrhagic effect.
